Pro Medicus is a healthcare IT company specializing in radiology imaging software... Show more
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PMCUF advanced for three days, in of 84 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on September 17, 2025. You may want to consider a long position or call options on PMCUF as a result. In of 67 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PMCUF just turned positive on September 17, 2025. Looking at past instances where PMCUF's MACD turned positive, the stock continued to rise in of 34 cases over the following month. The odds of a continued upward trend are .
PMCUF moved above its 50-day moving average on September 22, 2025 date and that indicates a change from a downward trend to an upward trend.
The Aroon Indicator entered an Uptrend today. In of 284 cases where PMCUF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for PMCUF crossed bearishly below the 50-day moving average on August 26, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
PMCUF broke above its upper Bollinger Band on September 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PMCUF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PMCUF's P/B Ratio (126.582) is slightly higher than the industry average of (22.554). PMCUF has a moderately high P/E Ratio (282.220) as compared to the industry average of (83.496). PMCUF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.857). Dividend Yield (0.002) settles around the average of (0.060) among similar stocks. P/S Ratio (153.846) is also within normal values, averaging (68.732).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ServicestotheHealthIndustry